Scarica l'app Stockscreener
5.455
2.06%
-0.115
Dopo l'orario di chiusura:
5.40
-0.055
-1.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$5.57
Aprire:
$5.49
Volume 24 ore:
2.26M
Relative Volume:
0.88
Capitalizzazione di mercato:
$420.11M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-3.3262
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-8.93%
1M Prestazione:
-17.47%
6M Prestazione:
-21.62%
1 anno Prestazione:
-47.50%
Intervallo 1D:
$5.225
$5.5679
Intervallo di 1 settimana:
$5.225
$6.09
Portata 52W:
$5.225
$11.50
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.455 | 420.11M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com
Altimmune, Inc. to Host Earnings Call - ACCESS Newswire
Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World
Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times
Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq
Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan
Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
H.C. Wainwright maintains Altimmune stock Buy rating, $12 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Altimmune stock Buy rating, $12 target - Investing.com India
Altimmune (NASDAQ:ALT) Receives “Buy” Rating from HC Wainwright - Defense World
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
(ALT) On The My Stocks Page - Stock Traders Daily
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Altimmune to Participate in the Leerink Global Healthcare Conference - The Manila Times
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
B. Riley Has Optimistic Outlook of Altimmune FY2025 Earnings - Defense World
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc. - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
William Blair Begins Coverage on Altimmune (NASDAQ:ALT) - Defense World
Altimmune Inc (ALT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs - GuruFocus.com
William Blair Initiates Coverage of Altimmune (ALT) with Market Perform Recommendation - MSN
Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83 - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Call Transcript - MSN
Altimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print - NewsBreak
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga India
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due In Q2 - Seeking Alpha
William Blair Initiates Coverage of Altimmune (LSE:0A4C) with Market Perform Recommendation - Nasdaq
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
William Blair Initiates Altimmune at Market Perform -February 28, 2025 at 07:51 am EST - Marketscreener.com
Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Altimmune, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationALT - ACCESS Newswire
Altimmune Reports Progress in Clinical Trials and Financials - TipRanks
Shareholders that lost money on Altimmune, Inc. (ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Altimmune Files For Mixed Shelf Offering Of Up To $400 Million- SEC Filing -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Altimmune reports Q4 EPS (33c), consensus (34c) - TipRanks
Earnings call transcript: Altimmune Q4 2024 sees stock surge 7.41% By Investing.com - Investing.com South Africa
Earnings call transcript: Altimmune Q4 2024 sees stock surge 7.41% - Investing.com
Altimmune Reports 2024 Financial Results and R&D Progress - TipRanks
ALTIMMUNE Earnings Results: $ALT Reports Quarterly Earnings - Nasdaq
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Can Altimmune's $131.9M War Chest Fuel Its Pemvidutide Program Through Critical MASH Readout? - StockTitan
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):